CK Life Sciences Int'l. (Holdings) Full Year 2022 Earnings: EPS: HK$0.014 (vs HK$0.017 in FY 2021)
CK Life Sciences Int'l. (Holdings) (HKG:775) Full Year 2022 Results
Key Financial Results
- Revenue: HK$5.28b (down 2.3% from FY 2021).
- Net income: HK$132.0m (down 19% from FY 2021).
- Profit margin: 2.5% (down from 3.0% in FY 2021). The decrease in margin was driven by lower revenue.
- EPS: HK$0.014 (down from HK$0.017 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CK Life Sciences Int'l. (Holdings) shares are down 4.9% from a week ago.
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with CK Life Sciences Int'l. (Holdings), and understanding them should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether CK Life Sciences Int'l. (Holdings) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
CK Life Sciences Int'l. (Holdings)
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America.
Overvalued with worrying balance sheet.